1. Prone Breast Irradiation

    Innovative Cancer Institute (ICI) in South Miami, Florida launches program of radiotherapy of breast cancer in the prone position to better protect the heart and lungs of the patients during treatment with external beam radiation therapy (EBRT).


AeroForm Tissue Expander

Patients with breast cancer that require breast reconstruction and need implants may benefit with the AeroForm Tissue Expander System.  At Innovative Cancer Institute, we are currently using radiation therapy in these patients. 


What is the AeroForm?

The AeroForm is a skin expander that uses Co2 to extend the breast to prepare it for reconstructive surgery without the need of repeated visits to the doctor or saline injection to expand the implant.  It is controlled by the patient at their pace.  The device is comprised by two primary components: the AeroForm Tissue Expander and the AeroForm Dosage Controller. With one press of the single-touch button, the Controller syncs with the Expander and a dose of 10cc of carbon dioxide is released, allowing the Expander to gradually expand.





  1. AeroForm Tissue Expander

    1- MMV™ Technology

  2. Smart-wave technology syncs the Dosage Controller with our proprietary microvalve system inside the Tissue Expander to deliver a precise dose of CO2.

  3. 2- CO2 Reservoir

  4. Aerospace-inspired design stores compressed CO2.

  5. 3- Anatomically-Shaped Inner Liner

  6. Retains delivered CO2 with lower pole projection.

  7. 4- Silicone Shell & Suture Tabs

  8. Designed for optimal surgical placement and minimal migration of Expander.


AeroForm Dosage Controller
  1. 5- MMV™ Technology

  2. Smart-wave technology syncs the Dosage Controller with our proprietary microvalve system inside the Tissue Expander to deliver a precise dose of CO2.

  3. 6- Intelligent Lighting Bank

  4. Provides visual and audible real time information on Expander fill level.

  5. 7- Single-Touch Button

  6. Allows the patient to independently dose up to 3 times a day.

To know More



Perspectives on Patient Access to Radiation Oncology Services in South America

Cancer represents fast-growing challenge worldwide, and is being recognized as an emerging and critical issue in low-and middle-income countries, such most of South America.
This sub-continent is unique for its geography, culture, and ethnical diversity. Most of its countries havelargeexpansesofjungleanddesertwhereunderservedpopulationgroups including indigenous (native Indians), represent a challenge for cancer care. Many indigent patients have no access to preventive care nor early diagnosis. This results in late presentations with advanced disease and frequently incurable cancer.  Prompt and coordinated action fromlocalandinternationalorganizationsisneededtosupportandguidelocal governments to avoid a global crisis. The critical role of education to improve awareness of the importance of radiation therapy, a cost-effective treatment modality, with the potential to help these patients at a relatively low cost is discussed.
Semin Radiat Oncol27:169-175 C 2017 Elsevier Inc. All rights reserved.


Status of Radiation Therapy in Uruguay: Past, Present, and Future.

By Beatriz Amendola, MD, FACR, FASTRO, FACRO, and Marco Amendola, MD, FACR, FSAR, Innovative Cancer Institute, South Miami, Florida


Women with advanced breast cancer are surviving longer, study says

The number of women living with advanced breast cancer is rising substantially in the United States, reflecting improved survival among all ages, according to a study published Thursday.

The study found that between 1992 and 1994, and 2005 and 2012, the five-year survival rate among women under age 50 initially diagnosed with advanced disease doubled from 18 percent to 36 percent. The median survival time for that group increased from 22.3 months to almost 39 months. For women ages 50 to 64, the survival time grew from a little more than 19 months to almost 30 months.

The lead author, Angela Mariotto of the National Cancer Institute, called the findings “favorable” because they were partly due to longer survival times resulting from better treatments. For example, the drug Herceptin,

which was approved in the late 1990s, has been shown to lengthen the lives of women with certain aggressive breast cancers.

The researchers calculated that more than 154,000 women are currently living with cancer that has spread beyond the breast, the most serious form of the disease.


Mariotto, who is chief of the Data Analytics Branch in the NCI's Division of Cancer Control and Population Sciences, said the study didn't explore why younger women survived longer, but one possibility was that they received more aggressive treatment. Patients with Stage 4 breast cancer — the most advanced — have the most intensive health-care needs, and advocacy groups, providers and researchers are increasingly interested in knowing how many are affected. The study estimated that the number rose by 4 percent from 1990 to 2000 and by 17 percent from 2000 to 2010. From 2010 to 2020, it is projected to increase by almost a third. Metastatic breast cancer once was considered an immediate death sentence, and it's still largely incurable, the researchers said. But new therapies targeting the triggers of the disease as well as improved palliative care mean women “can and often do live for years with reasonable quality of life, albeit undergoing constant treatment to keep their disease under control,” they said.
Contact us 305 669-6833